science wire

« BACK

Pharmacology



Results 1151 - 1200 of 1501.


Life Sciences - Pharmacology - 17.11.2013
How botox binds to neurons
How botox binds to neurons
Media Releases Biology Research Using Synchrotron Light Human Health Researchers elucidate how botulinum neurotoxin A binds to its protein receptor and thus provide a basis for the development of new drugs Botulinum neurotoxin A, better known as botox, is a highly dangerous toxin that causes paralysis in man that may prove fatal.

Pharmacology - Innovation - 14.11.2013
Novartis announces positive clinical trial results for novel H7N9 vaccine
85% of subjects immunologically protected after receiving second dose of investigational cell culture vaccine when combined with proven MF59 adjuvant Vaccine now in large scale production highlightin

Health - Pharmacology - 23.10.2013
Alcon receives positive NICE recommendation for Jetrea to treat eligible patients with vitreomacular traction, including macular hole
One-time single eye injection of Jetrea recognized as clinically and cost-effective treatment for eligible patients with vitreomacular traction, including macular hole Jetrea is the first and only ap

Business / Economics - Pharmacology - 22.10.2013
Novartis delivers strong sales performance in third quarter driven by growth products’ momentum; innovation newsflow reinforces growth prospects
Group net sales up 4% (+6% cc ) to USD 14.3 billion in third quarter and up 2% (+4% cc) in first nine months; all divisions contributed to growth Negative currency impact of 6 percentage points

Pharmacology - Health - 05.10.2013
Novartis announces positive results from final Phase III omalizumab registration study in severe form of chronic skin disease CSU
Omalizumab significantly reduced itch and hives caused by chronic spontaneous urticaria (CSU) as early as Week 1; benefit sustained over 24 weeks of active treatment Omalizumab 300 mg was nearly twice as effective in improving patients' quality of life within 12 weeks of treatment versus placebo ASTERIA I is the final omalizumab CSU registration study to be presented; regulatory applications were filed with EU and US authorities in Q3 2013 CSU i

Health - Pharmacology - 04.10.2013
New data show Novartis’ Gilenya reduced brain volume loss by one third and confirm brain volume loss link with disability in MS patients
New four-year data showed that continued Gilenya treatment reduced brain volume loss by one third when compared to delaying Gilenya by two years. MS patients with higher rates of brain volume loss were more likely to experience disease progression. Patients who remained free of disease had consistently lower rates of brain volume loss compared to patients who experienced disease activity.

Pharmacology - Health - 03.10.2013
Secukinumab showed superiority over Enbrel in clearing skin
Secukinumab (AIN457) patients' skin cleared faster and for longer than Enbrel (etanercept) patients, beginning as early as Week 2 Study also showed twice as many secukinumab patients experienced clear or almost clear skin by Week 12 versus Enbrel Head-to-head study of secukinumab and Enbrel part of largest clinical program completed in moderate-to-severe plaque psoriasis with more than 3,300 patients Secukinumab is the first IL-17A inhibitor wit

Pharmacology - Health - 03.10.2013
Real-world evidence showed superiority of Novartis’ Gilenya to reduce MS relapse rates compared to interferons or glatiramer acetate
Real-world data showed Gilenya reduced the annualized relapse rate and risk of relapse by around 50% versus interferons or glatiramer acetate Reducing the frequency and probability of future relapses in patients with MS is a key treatment goal, as relapses can significantly advance an individual's level of disability Recovering from a relapse can take weeks or months for a patient with MS, and approximately half of all relapses may leave lasting

Health - Pharmacology - 01.10.2013
FDA grants Roche’s Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer
FDA grants Roche's Perjeta accelerated approval for use before surgery in people with HER2-positive early stage breast cancer The Perjeta regimen is the first treatment approved under a new FDA pathw

Pharmacology - Health - 30.09.2013
Novartis to reveal landmark Phase III results from specialty dermatology portfolio at upcoming EADV 2013 congress
Data from head-to-head pivotal study showing secukinumab (AIN457) superiority to Enbrel * (etanercept) in moderate-to-severe plaque psoriasis to be revealed Results from three additional secukinumab Phase III studies also to be presented for the first time Secukinumab is the first IL-17A inhibitor with Phase III data and is on track to be the first psoriasis medication filed targeting IL-17A New data to be reported from final omalizumab registra

Pharmacology - Health - 27.09.2013
New data for Novartis drug Lucentis reinforces transformational efficacy and well-established safety profile across four indications
Pivotal myopic CNV trials with Lucentis (ranibizumab) show visual acuity improvement of nearly 14 letters with a median of two injections at one year New data suggest early treatment initiation with Lucentis results in better vision gains in DME patients Meta-analysis of 14 trials and 6504 patients confirms well-established Lucentis safety profile reported from real-world experience and extensive clinical trials Basel, September 27, 2013 - New c

Pharmacology - Life Sciences - 25.09.2013
Data at ECTRIMS to confirm Novartis’ Gilenya long-term efficacy on reducing brain volume loss and real-world relapse rates in MS
New four-year data will show continued Gilenya treatment reduced brain volume loss in MS patients compared to delaying treatment with Gilenya by two years Data will strengthen the link between brain volume loss and disability progression, highlighting the importance of reducing brain volume loss in patients with MS Real-world patient data will confirm superiority of Gilenya compared to standard therapies (interferon and glatiramer acetate) in re

Pharmacology - Health - 23.09.2013
Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan
Ultibro Breezhaler (QVA149) is the first once-daily dual bronchodilator to gain European Commission approval as a maintenance bronchodilator treatment to relieve symptoms in adult patients with COPD In Japan, once-daily Ultibro Inhalation Capsules (QVA149), delivered through the Breezhaler device, approved for relief of various symptoms due to airway obstruction in COPD Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standards of care - .

Pharmacology - Health - 23.09.2013
Malaria No More and Novartis launch Power of One, a global digital fundraising campaign to help eliminate malaria deaths
Power of One enables the public to fund malaria tests and treatments for children in Africa through the latest online and mobile technology Novartis is the exclusive campaign treatment sponsor and wi

Pharmacology - Health - 19.09.2013
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
CML community recognizes September 22 as World CML Day to raise awareness of the needs of patients living with CML Novartis commemorates World CML Day, announcing 100+ study sites across 40 countries now enrolling patients to its global treatment-free remission clinical trials Treatment-free remission program evaluates whether patients can maintain undetectable levels of disease after stopping nilotinib therapy Basel, September 19, 2013 - Novart

Health - Pharmacology - 08.09.2013
Novartis data presented at ERS showcases once-daily COPD portfolio and further demonstrates efficacy of Ultibro Breezhaler (QVA149)
New analyses in the IGNITE clinical trial program showed that QVA149 provided superior, rapid and sustained improvements in lung function and significantly reduced shortness of breath versus comparator therapies , BLAZE study also demonstrated significant improvements in shortness of breath with QVA149 compared to tiotropium 18 mcg in patients with moderate-to-severe COPD SPARK study showed similar rates of reduction in exacerbations with once-d

Pharmacology - Health - 06.09.2013
Novartis announces an exclusive global licensing and research collaboration with Regenerex, leveraging a novel cell platform to broaden presence in the cell therapy space
Research collaboration advances company goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need Strategic research collaboration enlarges scop

Pharmacology - Health - 04.09.2013
Novartis marks 30 year anniversary in transplantation and reinforces continued commitment to organ recipients at ESOT congress
Novartis reaffirms continued innovation in transplant during anniversary year of breakthrough therapy, ciclosporin TRANSFORM trial to be presented : largest ever study of its kind, evaluating Certica

Health - Pharmacology - 04.09.2013
Novartis showcases 39 abstracts highlighting robust respiratory portfolio at ERS 2013
Robust efficacy of once-daily Ultibro Breezhaler (QVA149) supported by a pooled analysis of the Phase III IGNITE clinical trial program further strengthens evidence for the Ultibro LABA+LAMA combination for the treatment of COPD patients , , Once-daily Seebri Breezhaler (glycopyrronium) efficacy data strengthened by new analyses from the SPARK study on exacerbations and lung function in severe and very severe COPD patients , Basel, September 4,

Pharmacology - Health - 03.09.2013
Novartis receives EU approval for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
Ilaris is the first interleukin-1 beta (IL-1 beta) inhibitor for the treatment of Systemic Juvenile Idiopathic Arthritis (SJIA) and is the only treatment approved specifically for SJIA that is given

Health - Pharmacology - 02.09.2013
Novartis’ serelaxin (RLX030) improved symptoms and mortality across multiple subgroups of patients with acute heart failure[1],[2]
New analysis of RELAX-AHF published in the European Heart Journal and presented as a late breaker at the European Society of Cardiology congress , If approved, RLX030 has the potential to be the first treatment breakthrough for AHF patients in 20 years , Basel, September 2, 2013 - Results from a new analysis of the Phase III RELAX-AHF study published today in the European Heart Journal and presented as a late breaker at the European Society of C

Pharmacology - Health - 20.08.2013
Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)
BYM338 is the third Novartis investigational treatment this year to receive a breakthrough therapy designation by the FDA, highlighting Novartis' leadership in the industry in breakthrough therapy designations Basel, August 20, 2013 - Novartis announced today that the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to BYM338 for sporadic inclusion body myositis (sIBM).

Health - Pharmacology - 15.08.2013
Novartis vaccine Bexsero approved in Australia to help protect against MenB disease, a deadly form of bacterial meningitis
Australia approval marks a key step in expanding access to the first and only broad coverage vaccine against MenB disease , ; Bexsero was granted European licensure this past January MenB disease is

Health - Pharmacology - 08.08.2013
Novartis first company accredited with global "CEO Cancer Gold Standard" for outstanding efforts in cancer prevention and treatment
The non-profit CEO Roundtable on Cancer has recognized the programs Novartis has to support associates in the prevention, diagnosis and treatment of cancer Originally recognized for these efforts in

Health - Pharmacology - 07.08.2013
Study of Afinitor in advanced liver cancer does not meet primary endpoint of overall survival
Everolimus did not show survival benefit for patients with advanced hepatocellular carcinoma (HCC) after progression on or intolerance to sorafinib Study results do not impact use of Afinitor in othe

Health - Pharmacology - 01.08.2013
FDA expands age indication for Menveo , first and only quadrivalent meningococcal vaccine for infants as young as 2 months of age[1]
Meningococcal disease is a leading cause of bacterial meningitis, a rapidly progressing disease that can lead to death in otherwise healthy children , The highest rates of meningococcal disease in th

Health - Pharmacology - 26.07.2013
Novartis receives positive CHMP opinion for Ilaris in active Systemic Juvenile Idiopathic Arthritis, a serious form of childhood arthritis
The CHMP has endorsed the use of Ilaris in patients aged 2 years and older who suffer from Systemic Juvenile Idiopathic Arthritis (SJIA) In Phase III studies, 84% of Ilaris-treated SJIA patients achi

Health - Pharmacology - 26.07.2013
Novartis first in class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) gains positive CHMP opinion for the treatment of COPD
QVA149 (indacaterol/glycopyrronium) is the first once-daily fixed-dose combination of both a LABA and a LAMA bronchodilator to gain positive CHMP opinion Pivotal Phase III IGNITE data showed QVA149 significantly improved lung function and patient-reported outcomes including breathlessness and rescue medication use, compared to current standard of care QVA149 demonstrated significantly reduced rates of COPD exacerbations and improved health-relat

Health - Pharmacology - 24.07.2013
UK children remain unnecessarily at risk for life-threatening and disabling meningitis B disease, following JCVI interim recommendation on Novartis Bexsero vaccine
JCVI takes interim position to not recommend Bexsero for the routine immunization program, driven by evaluation based on cost-effectiveness assumptions The evaluation by JCVI was made prior to any pr

Pharmacology - Chemistry - 24.07.2013
A new method for clicking molecules together
A new method for clicking molecules together
Scientists at EPFL have developed a quick and simple method for connecting and assembling new molecules together, paving a new road for synthetic chemistry, material science, chemical biology, and even drug discovery. Thiols are sulfur-containing molecules found in most proteins of the human body. Characterized by their 'garlicky' smell, they also give coffee, sweat and the spray of skunks their unique odor.

Health - Pharmacology - 19.07.2013
Molecular validation of novel breast cancer therapeutic target
Under the leadership of Nancy Hynes, scientists from the Friedrich Miescher Institute for Biomedical Research have identified a potential novel target for breast cancer treatment. The scientists could show that breast cancer patients with high levels of the receptor tyrosine kinase Ret have a worse prognosis; and that blocking Ret not only decreases tumor growth but also impacts the potential of the cancer to spread throughout the body.

Business / Economics - Pharmacology - 17.07.2013
Novartis delivered growth across all divisions in second quarter (cc); raises guidance for full year 2013
Group net sales increased 1% (+3% cc ) versus year ago to USD 14.5 billion in second quarter, up 2% (+4% cc) to USD 28.5 billion in first half Core operating income was USD 3.8 b

Health - Pharmacology - 08.07.2013
Novartis and Biological E agree to deliver affordable vaccines for typhoid and paratyphoid A fevers to developing world
License agreement advances a Novartis goal to deliver accessible and affordable vaccines that address unmet medical need in endemic regions More than 21 million cases of typhoid fever and five millio

Pharmacology - Health - 08.07.2013
Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel in head-to-head Phase III psoriasis study
FIXTURE trial of more than 1,300 moderate-to-severe plaque psoriasis patients showed superiority of secukinumab (AIN457) to Enbrel (etanercept) FIXTURE is a pivotal trial for registration; Regulatory submissions for secukinumab (AIN457), a therapy targeting IL-17A, are on tr ack for the second half of 2013 Basel, July 8, 2013 - Novartis announced today top-line results from the head-to-head Phase III psoriasis study which showed the superiority of secukinumab (AIN457) in clearing skin to Enbrel * (etanercept), an anti-tumor necrosis factor (anti-TNF) therapy.

Pharmacology - Health - 05.07.2013
Novartis drug Lucentis approved in EU as first effective anti-VEGF treatment for myopic choroidal neovascularization
Lucentis (ranibizumab) is the first licensed therapy to improve vision in patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Pivotal trial shows average visual acuity improvement of up to 14 letters at one year with a median of only two injections with Lucentis treatment Myopic CNV, the growth of abnormal leaky blood vessels in the back of the eye in high myopia, often causes irreversible deteriora

Health - Pharmacology - 26.06.2013
Novartis reports new Phase III data showing omalizumab significantly improves itch in patients with severe form of chronic skin disease CSU[1]
Omalizumab met all primary and secondary endpoints in pivotal GLACIAL study of patients with refractory chronic spontaneous urticaria (CSU) Omalizumab found to be effective, safe and well tolerated in refractory CSU patients, including those on antihistamines at up to four times the approved dose By Week 12 omalizumab eliminated or suppressed symptoms in more than half of patients who failed multiple therapies; benefit sustained during active tr

Pharmacology - Health - 24.06.2013
Sandoz launches Phase III clinical trial for biosimilar etanercept
Holzkirchen, Germany, June 24, 2013 - Sandoz, the global leader in biosimilars, announced it has initiated a major Phase III clinical trial with its biosimilar version of etanercept (Amgen's Enbrel ).

Pharmacology - Health - 21.06.2013
FDA grants Breakthrough Therapy designation to Novartis’ serelaxin (RLX030) for acute heart failure
Recognition by the US Food and Drug Administration (FDA) that RLX030 has the potential to address a serious unmet medical need If approved, RLX030 has the potential to be the first treatment breakthrough for Acute Heart Failure patients in 20 years[1,2] RLX030 is the second Breakthrough Therapy designation by the FDA for Novartis investigational treatments, following LDK378 Basel, June 21 , 2013 - Novartis announced today that the US Food and Dr

Pharmacology - Health - 16.06.2013
Novartis drug Jakavi improved overall survival of myelofibrosis patients and impacted an underlying mechanism of disease
Jakavi reduced risk of death by 52% and sustained reductions in spleen size in new three-year COMFORT-II study data Analysis from a separate trial suggested that long-term treatment with Jakavi may stabilize or improve bone marrow fibrosis, a key marker of worsening disease Basel, June 16, 2013 - Novartis today announced results from a Phase III three-year follow-up study that showed Jakavi (ruxolitinib) demonstrated improved overall survival and sustained reductions in spleen size compared to conventional therapy.

Pharmacology - Life Sciences - 10.06.2013
Switching to Novartis drug Gilenya from standard interferon shown to improve long-term outcomes for patients with multiple sclerosis
Gilenya resulted in almost 50% more patients being free of MS disease activity after the switch from standard interferon treatment Annualized relapse rate reduced by >50% after 1 year for patients who switched from standard interferon treatment to Gilenya Reduced rate of brain volume loss sustained for up to 4.5 years in patients with active disease, despite prior treatment, who switched from interferon to Gilenya Basel, June 10 , 2013

Pharmacology - Health - 05.06.2013
New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis
Gilenya improved the key measures: brain volume loss, MRI lesion activity, relapse rates and disability progression Switching to Gilenya from interferon increased the proportion of patients disease free after one year of treatment Gilenya resulted in sustained reduction of annualized relapse rate and the rate of brain volume loss in patients switched from interferon treatment Basel, June 5 , 2013 - New data will be presented at the 23 rd meeting

Pharmacology - Health - 03.06.2013
Novartis Breakthrough Therapy LDK378 shows a marked clinical response in patients with ALK+ non-small cell lung cancer
Investigational compound LDK378 is a selective inhibitor of ALK , a target found in metastatic non-small cell lung cancer (NSCLC) Data show 60% overall response rate in 78 patients with ALK+ NSCLC taking LDK378 at 750 mg; will serve as basis for first filing in early 2014 FDA designated LDK378 as Breakthrough Therapy in March and a robust clinical development plan is underway Basel, June 3 , 2013 - Novartis today announced data on its investigat

Health - Pharmacology - 02.06.2013
Novartis pivotal Phase III trial shows Afinitor significantly delays tumor growth in HER2 positive advanced breast cancer
A 22% reduction in the risk of disease progression was seen with the addition of everolimus, an mTOR inhibitor, to trastuzumab and vinorelbine in heavily pretreated patients First Phase III study sho

Health - Pharmacology - 31.05.2013
Lucentis receives positive opinion for patients with myopic choroidal neovascularization showing vision gains with only two injections
Lucentis recommended for approval in EU to treat patients with visual impairment due to choroidal neovascularization secondary to pathologic myopia Lucentis superior to current standard of care and i

Health - Pharmacology - 29.05.2013
Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
Latest Phase III research on Afinitor in HER2 positive advanced breast cancer Jakavi TM overall survival advantage evaluated in three-year study in patients with myelofibrosis, a rare and life-threat

Pharmacology - Health - 29.05.2013
World MS Day: Novartis launches a new campaign to raise awareness of MS and the unique experiences of people living with the disease
New campaign 'MS and:Our Story' announced today, providing MS community with platform to share experiences of life with MS Launch of new Novartis social media platforms to help generate dialogue, inf

This site uses cookies and analysis tools to improve the usability of the site. More information. |